There are currently 452 clinical trials in Rochester, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Rochester, University of Rochester Medical Center, James P. Wilmot Cancer Center at University of Rochester Medical Center and Rochester Clinical Research, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: University of Rochester, Rochester, New York
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05916339
Recruiting
This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to me... Read More
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
08/07/2024
Locations: University of Rochester, Rochester, New York
Conditions: ADHD, Autism Spectrum Disorder
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Rochester Clinical Research, Rochester, New York
Conditions: Ulcerative Colitis
Register for Updates
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
NCT06477640
Recruiting
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Pulmonary Arterial Hypertension PAH
Register for Updates
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
NCT04645810
Recruiting
The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/03/2024
Locations: University of Rochester, Rochester, New York
Conditions: Prostate Cancer, HDR
Register for Updates
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892
Recruiting
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
08/02/2024
Locations: GSK Investigational Site, Rochester, New York
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.
NCT04608149
Recruiting
The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription. A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem™... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2024
Locations: Golisano Children's Hospital, Rochester, New York
Conditions: Acute Kidney Injury, Fluid Overload
Register for Updates
Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy
NCT06531876
Recruiting
This study intends to examine the utility of a home-use EEG-based sleep monitor for the diagnosis and evaluation of disorders of excessive sleepiness, specifically the neurological disorder Narcolepsy Type 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Sleep Insights Medical Associates PLLC, Rochester, New York
Conditions: Narcolepsy Type 1, Hypersomnia, Sleep Disorder
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Rochester Clinical Research, Rochester, New York
Conditions: Ulcerative Colitis
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
NCT04922281
Recruiting
To prospectively investigate the efficacy of an insertable cardiac monitor-guided atrial fibrillation (AF) management in reducing subsequent AF burden in patients with persistent or paroxysmal AF undergoing atrial catheter ablation (CA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes
Register for Updates
Regeneron AA Multicenter (Dupilumab)
NCT05551793
Recruiting
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers through Week 48. AA subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥ 200 and/or have personal and/or familial history of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: UR Dermatology at College Town, Rochester, New York
Conditions: Alopecia Areata
Register for Updates